NASDAQ : LGND
Ligand Pharmaceuticals Incorporated — Key statistics
Healthcare · Biotechnology · United States
Last price 317.33 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.46B |
| Enterprise Value | 7.16B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 20.00M |
| Shares Outstanding | 20.00M |
| Shares Change (YoY) | +10.50% |
| Shares Change (QoQ) | -8.59% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 115.37% |
| Float | 19.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 134.96 |
| Forward PE | 44.68 |
| PS Ratio | 25.43 |
| Forward PS | 18.49 |
| PB Ratio | 6.71 |
| P/TBV Ratio | 14.29 |
| P/FCF Ratio | 71.24 |
| P/OCF Ratio | 70.92 |
| PEG Ratio | 1.83 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 139.19 |
| EV / Sales | 28.22 |
| EV / EBITDA | 100.21 |
| EV / EBIT | 196.20 |
| EV / FCF | 79.03 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.22 |
| Quick Ratio | 1.16 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | 16.01 |
| Debt / FCF | 12.74 |
| Interest Coverage | 4.46 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 5.38% |
| Return on Assets (ROA) | 1.23% |
| Return on Invested Capital (ROIC) | 2.96% |
| Return on Capital Employed (ROCE) | 2.10% |
| Weighted Average Cost of Capital (WACC) | 8.41% |
| Revenue Per Employee | $5.40M |
| Profits Per Employee | $1.09M |
| Employee Count | 47 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 2.67 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.27M |
| Effective Tax Rate | 2.41% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +74.91% |
| 50-Day Moving Average | 296.39 |
| 200-Day Moving Average | 252.66 |
| Relative Strength Index (RSI) | 63.39 |
| Average Volume (20 Days) | 234,692 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.50M |
| Short Previous Month | 2.68M |
| Short % of Shares Out | 12.51% |
| Short % of Float | 12.79% |
| Short Ratio (days to cover) | 9.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 253.83M |
| Gross Profit | 218.61M |
| Operating Income | 36.51M |
| Pretax Income | 52.73M |
| Net Income | 51.46M |
| EBITDA | 71.48M |
| EBIT | 36.51M |
| Earnings Per Share (EPS) | $2.39 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 447.40M |
| Total Debt | 1.15B |
| Net Cash | -706.81M |
| Net Cash Per Share | -$35.34 |
| Equity (Book Value) | 961.76M |
| Book Value Per Share | 48.09 |
| Working Capital | 107.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 91.03M |
| Capital Expenditures | -405,000 |
| Depreciation & Amortization | 34.97M |
| Net Borrowing | 504.18M |
| Free Cash Flow | 90.63M |
| FCF Per Share | $4.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.12% |
| Operating Margin | 14.38% |
| Pretax Margin | 20.77% |
| Profit Margin | 20.27% |
| EBITDA Margin | 28.16% |
| EBIT Margin | 14.38% |
| FCF Margin | 35.70% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.50% |
| Shareholder Yield | -10.50% |
| Earnings Yield | 0.74% |
| FCF Yield | 1.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $350.92 |
| Price Target Difference | 8.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 18.26% |
| EPS Growth Forecast (3Y) | 21.64% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 19, 2010 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |